Advisors Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Advisors Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$73.5K	Sell	3,942 -50	-1%	-$828	﹤0.01%	1265
2025 Q4	$52.6K	Sell	3,992 -2	-0.1%	-$24	﹤0.01%	1303
2025 Q3	$28.6K	Sell	3,994 -15	-0.4%	-$782	﹤0.01%	1333
2025 Q2	$189K	Hold	4,009	–	–	﹤0.01%	1124
2025 Q1	$157K	Buy	4,009 +1,803	+82%	+$77.7K	﹤0.01%	1137
2024 Q4	$119K	Buy	+2,206	New	+$113K	﹤0.01%	1195

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Advisors Asset Management's MLTX Position: Q1 2026 in Review

Advisors Asset Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 1.3% in Q1 2026, selling an estimated $828 and leaving 3,942 shares worth $73.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1265.

Advisors Asset Management first reported a position in MLTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $189K in Q2 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Advisors Asset Management held 3,942 shares of MoonLake Immunotherapeutics worth $73.5K as of Q1 2026.
Advisors Asset Management sold 50 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $828.
MoonLake Immunotherapeutics made up ﹤0.01% of Advisors Asset Management's portfolio in Q1 2026, its #1265 holding.
Advisors Asset Management first reported a position in MoonLake Immunotherapeutics in Q4 2024 and has held it in 6 quarters since.
Advisors Asset Management's MoonLake Immunotherapeutics position peaked at $189K in Q2 2025.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.